Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alkaline glucosodiene is a novel compound described as an alkaline isomer or polymer of glucose, synthesized by reacting dextrose (glucose) with sodium bicarbonate. The resulting molecule, identified as 1-2-O-β-D-Glucopyranosyl-α-D-glucose (C12H22O11), forms a polymer through 1-2 linkages and exhibits properties distinct from native glucose. Its proposed mechanism of action targets cancer cell metabolism—specifically the Warburg effect—by exploiting cancer cells' high avidity for glucose. When taken up by tumor cells via their glucose transporters, the modified structure and alkalinity are hypothesized to disrupt cellular metabolism and pH balance, leading to selective cytotoxicity in cancerous tissue while sparing normal cells. Preclinical studies and early case reports suggest potential efficacy in solid tumors such as triple-negative breast cancer with bone metastasis; however, its chemical structure requires further validation and clinical evidence remains limited[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alkaline glucosodiene.